Intermountain Heart Institute at Intermountain Medical Center

(801) 507-4701Map5121 S. Cottonwood StreetMurray, UT 84107
Intermountain Heart Institute logo
Heart Valve & Structural Heart Disease Program
Questions & Referrals:
(801) 507-4795

Video

Install Flash Player to View this Video

The Structural Heart Disease Program is the only program in the Intermountain West to be invited to participate in the clinical trials listed here. Click on a condition or procedure listed below to view trial information. Please contact us at 801-507-4795 for further information.

Jump to:

Aortic Stenosis

Trial: Partner II Trial
Long Title: Placement of Aortic Transcatheter Valves Trial
Principal Investigators: Brian Whisenant, MD and Kent Jones, MD
Sponsor: Edwards Lifesciences, LLC
Description: The purpose of the PARTNER II trial is to determine the safety and effectiveness of the Edwards SAPIEN XT device and NovaFlex delivery systems in inoperable patients with symptomatic critical aortic valve stenosis. Patients with critical aortic stenosis who are characterized as high risk for surgery or inoperable may be eligible for this study. The investigational replacement heart valve is compressed on a balloon and delivered to the heart via a catheter inserted into either the femoral artery in the leg (transfemoral) or a small incision between the ribs (transapical). This study is comparing the SAPIEN XT device to the original SAPIEN device used in the PARTNER I trial.

View PARTNER videos (top right) to see animations of less invasive transfemoral and transapical aortic valve implantation.

Mitral Regurgitation

Trial: REALISM - EVEREST II Continued Access Registry
Long Title: Real World Expanded Multicenter Study of the MitraClip System
Principal Investigator: Brian Whisenant, MD
Sponsor: Evalve, Inc., a subsidiary of Abbott Vascular
Description: Cardiologists at Intermountain Medical Center participated in the EVEREST II trial which compared the Evalve MitraClip device with standard open heart surgery in patients diagnosed with mitral regurgitation. The MitraClip device is placed via a catheter from the femoral vein and does not require a chest incision, use of a heart-lung machine, or stopping of the heart. The MitraClip device is now available at Intermountain Medical Center through participation in the REALISM registry. Select patients without surgical options may also be considered for emergency use or compassionate use of the MitraClip device.

View REALISM video (top right) to see animations of the MitraClip device.

Left Atrial Appendage (LAA) Closure

Trial: PREVAIL
Long Title: Evaluation of the Watchman LAA Closure Device in Patients with Atrial Fibrillation versus Long-term Wafarin Therapy
Principal Investigator: Brian Whisenant, MD
Sponsor: Atritech
Description: Cardiologists at Intermountain Medical Center have been leading participants in both the PROTECT AF Trial and the CAP Registry. These trials have demonstrated the safety and effectiveness of the Atritech Watchman Left Atrial Appendage closure device. The PREVAIL trial is an extension of the PROTECT AF and CAP studies. The goal of the PREVAIL study is to compare the effectiveness of the WATCHMAN Device versus standard medical treatment, warfarin, as an alternative for prevention of AF related stroke. Patients with non-valvular atrial fibrillation may be eligible to participate in this study. The device is investigational technology.

View PREVAIL video (top right) to see how the Watchman device is implanted in the cath lab to occlude the left atrial appendage.

Copyright © , Intermountain Healthcare, All rights reserved.